pubmed.ncbi.nlm.nih.gov

Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma - PubMed

️Sun Jan 01 2006

Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma

Sufi Mary Thomas et al. Cancer Res. 2006.

Abstract

G protein-coupled receptors (GPCR) and the epidermal growth factor receptor (EGFR) are often both overexpressed and contribute to the growth of cancers by activating autocrine pathways. GPCR ligands have been reported to trigger EGFR signaling via receptor cross-talk in cancer cells. Here, we show that GPCR ligands prostaglandin E2 (PGE2) and bradykinin (BK) activate EGFR signaling. Inhibition of EGFR using several strategies, including small-molecule inhibitors and an EGFR-specific antibody, resulted in partial attenuation of signaling downstream of EGFR. PGE2 and BK triggered EGFR signaling by increasing selective autocrine release of transforming growth factor-alpha (TGF-alpha). Inhibition of tumor necrosis factor-alpha-converting enzyme abrogated BK- or PGE2-mediated activation of EGFR signaling. Both PGE2 and BK stimulated head and neck squamous cell carcinoma (HNSCC) invasion via EGFR. Treatment of HNSCC cells with the BK antagonist CU201 resulted in growth inhibition. The combination of CU201 with the EGFR small-molecule inhibitor erlotinib resulted in additive inhibitory effects on HNSCC cell growth in vitro. Inhibition of the PGE2 synthesis pathway with sulindac induced HNSCC cytotoxicity at high doses (EC(50), 620 micromol/L). However, combined inhibition of both EGFR with the tyrosine kinase inhibitor erlotinib and GPCR with sulindac at low doses of 6 and 310 micromol/L, respectively, resulted in synergistic killing of HNSCC tumor cells. Combined blockade of both EGFR and GPCRs may be a rational strategy to treat cancers, including HNSCC that shows cross-talk between GPCR and EGFR signaling pathways.

PubMed Disclaimer

Cited by

Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.
Ferris RL, Jaffee EM, Ferrone S. Ferris RL, et al. J Clin Oncol. 2010 Oct 1;28(28):4390-9. doi: 10.1200/JCO.2009.27.6360. Epub 2010 Aug 9. J Clin Oncol. 2010. PMID: 20697078 Free PMC article. Review.
Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic Cancer Cells.
Lee S, Heinrich EL, Lu J, Lee W, Choi AH, Luu C, Chung V, Fakih M, Kim J. Lee S, et al. Pancreas. 2016 Feb;45(2):286-92. doi: 10.1097/MPA.0000000000000379. Pancreas. 2016. PMID: 26262587 Free PMC article.
A Brief History of Single-Particle Tracking of the Epidermal Growth Factor Receptor.
Clarke DT, Martin-Fernandez ML. Clarke DT, et al. Methods Protoc. 2019 Jan 30;2(1):12. doi: 10.3390/mps2010012. Methods Protoc. 2019. PMID: 31164594 Free PMC article. Review.
RNA interference-mediated silencing of G protein-coupled receptor 137 inhibits human gastric cancer cell growth.
Wang Z, Zhang H, Wang J, Yang Y, Wu Q. Wang Z, et al. Mol Med Rep. 2015 Apr;11(4):2578-84. doi: 10.3892/mmr.2014.3091. Epub 2014 Dec 15. Mol Med Rep. 2015. PMID: 25514843 Free PMC article.
Human rhomboid family-1 gene silencing causes apoptosis or autophagy to epithelial cancer cells and inhibits xenograft tumor growth.
Yan Z, Zou H, Tian F, Grandis JR, Mixson AJ, Lu PY, Li LY. Yan Z, et al. Mol Cancer Ther. 2008 Jun;7(6):1355-64. doi: 10.1158/1535-7163.MCT-08-0104. Epub 2008 Jun 4. Mol Cancer Ther. 2008. PMID: 18524845 Free PMC article.

Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma - PubMed